BMS’s Opdivo stumbles in late-stage cancer trial

May 9, 2019

Bristol-Myers Squibb’s Opdivo have become the company’s biggest driver of growth. But the immuno-oncology treatment recently hit a roadblock in a trial targeting patients with glioblastoma multiforme, which affects the central nervous system and can cause aggressive tumors in the brain or spine. 

According to the company, results from a recent study showed that when combined with radiation, the treatment failed to extend survival rates for patients compared to chemotherapy and radiation. 

Opdivo has already been approved to treat several types of cancer including skin and lung cancers. The drug raked in $1.8 billion in sales in the first quarter of this year. 

Read the full Reuters report.